Detección y tipificación del Virus Papiloma Humano en el marco del tamizaje virológico para la detección de lesiones del cuello uterino en Asunción, Paraguay

Maria Liz Bobadilla Frizzola, Verónica Villagra, Maria Elena Zorrilla, Gladys Olmedo, María Cristina Riveros, Francisco Franco, Hernando Rodríguez, Cristina Gonzalez Bado, Jorge Basiletti, María Alejandra Picconi

Resumen


En Paraguay la incidencia de cáncer de cuello uterino (CCU) es superior a las observadas en otros países de la región. El agente etiológico asociado al CCU es el virus papiloma humano (VPH), esencialmente tipos de alto riesgo oncogénicos. El objetivo es describir aspectos epidemiológicos de la infección genital por el virus papiloma humano de alto riesgo (VPH-AR) en mujeres de 25 a 64 años que consultaron en servicios de Patología Cervical del MSPyBS, de mayo a diciembre de 2013. Se utilizó el Cobas 4800 HPV Test (Roche) que permite la detección individual de VPH-16 y VPH-18 y un pool de otros VPH-AR que incluye 12 genotipos de alto riesgo. Los otros VPH-AR fueron tipificados por hibridación reversa en línea (RLB). Entre las 495 mujeres incluidas, se detectaron 72 casos positivos (14,5%) de VPH-AR. Se identificaron 19 tipos virales; siendo el más frecuente VPH-16 (2,1%), seguido del VPH-31, 33, 58 y 66; el VPH-18 aparece en sexto lugar. Este trabajo aporta los primeros datos sobre la implementación de técnicas moleculares para detección y tipificación de VPH como parte del sistema de salud pública de Paraguay. El predominio de VPH-16, confirma su amplia circulación a nivel mundial y dado su mayor potencial oncogénico, representa una alerta a considerar, en especial en las mujeres mayores de 30 años portadoras de una infección persistente. Estos resultados apoyan la importancia de la implementación criteriosa y la utilización apropiada de las pruebas moleculares actualmente disponibles para la prevención y control del CCU.

Palabras clave


virus papiloma humano; Cobas 4800 HPV-Test; genotipificación; cáncer de cuello uterino

Texto completo:

PDF

Referencias


Global Cancer Observatory. International Agency for Research on Cancer. WHO 2018. Estimated age-standarized cancer incidence, mortality and prevalence worldwide in 2018. Disponible en http://gco.iarc.fr/

Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjosé S, Bruni L et al. Epidemiology and natural history of human papillomavirus infections and type specific implications in cervical neoplasia. Vaccine. 2008; 26S:K1–K16.

Clifford GM, Gallius S, Herrero R, Muñoz N, Snijders PJF, Vaccarella S et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer

HPV prevalence surveys: a pooled analysis. Lancet. 2005;366: 991-98.

Estrade C, Menoud PA, Nardelli-Haefliger D, Sahli R. Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes. J Clin Microbiol. 2011; 49 (10): 3474-81.

Solomon D, Davey D, Kurman R, Moriaty A, O’Connor D, Prey M et al. Terminology for reporting results of cervical cytology. JAMA. 2002; 267(16):2114-19.

Mendoza LP, Arbiza J, Páez M, Kasamatsu E, Castro A, Giménez G et al. Características clínico-demográficas y tipificación del virus de papiloma humano en mujeres paraguayas con citologías negativas para lesión escamosa intraepitelial. Mem. Inst. Investig. Cienc. Salud. 2012; Vol. 10(1):46-55

Matos E, Loria D, Amestoy GM, Herrera L, Prince MA, Moreno J et al. Prevalence of Human Papillomavirus Infection Among Women in Concordia, Argentina: A Population-Based Study. Sexually transmitted diseases. 2003;30(8):593-99.

Ferreccio C, Prado R, Luzoro A. Prevalencia poblacional y distribución por edad del virus papiloma humano entre mujeres en Santiago, Chile. Boletín Escuela de Medicina. 2005; 30 (1): 34-9.

Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX and de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010 Dec 15;202(12):1789-99.

Wright TC, Stoler MH, Sharma A, Zhang G, Behrens C , Wright TL. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol. 2011 Oct;136(4):578-86.

Wellings K, Collumbien M, Slaymaker E Singh S, Hodges Z, Patel D, et al. Sexual behavior in context: a global perspective. Lancet. 2006;368:1706-28.

Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. The Lancet. 2007;370(9590):890-907.

Stanley MA, Sterling JC. Host responses to infection with human papillomavirus. In Human Papillomavirus. Karger Publishers. 2014; 45:58-74.

Rodríguez AC, Schiffman M, Herrero R et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008;100;513-17.

Castle PE, Solomeno D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005; 97: 1066-71.

De Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N and Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. The Lancet infectious diseases.2007;7(7): 453-9.

Cardozo Segovia FM, Mendoza Torres LP, Páez Acchiardi GM, Mongelós Dacunte PE, Castro Matto AM, Giménez Ortigoza G. Detección molecular de infecciones múltiples en mujeres con y sin lesión de cuello uterino positivas para el virus del papiloma humano de alto riesgo, período 2007-2011. Mem.

Inst. Investig. Cienc. Salud. 2012 Dec; 10(2):05-12.

Sasagawa T, Basha W, Yamazaki H, Inoue M. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol Biomark Prev. 2001;10:45-52.

Van der Graaf Y, Molijn A, Doornewaard H, Quint W, Van Doorn LJ y Van den Tweel J. Human papillomavirus and the long-term risk of cervical neoplasia. Am. J. Epidemiol. 2002;156:158-64.

Herrero R, Hildesheim A, Bratti C, Sherman ME et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000;92:464-74.

Bosch FX, Lorincz A, Muñoz N, Meijer CJ y Shah KV. The causal relation between papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-65.

Quint W, Jenkins D, Molijn A, Struijk L, Van der Sandt M, Doobar J, Mols J, Van Hoof C, Hardt K, Struyf F, Colau B. One virus, one lesion – individual components of CIN lesions contain a specific HPV type. J Pathol. 2012;May227(1):62-71

Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89:101-5.

Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev, 2005; 14: 1157-64.

Kjær SK, Frederiksen K, Munk C , Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. Journal of the National Cancer Institute. 2010;102(19):1478-88.

Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillén D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005, 337:76-84.

Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Nath Cancer Inst. 2005 Jul 20;97(14): 1072-79.

Muñoz N, Castellsagué X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology

Bobadilla ML et al Detección y tipificación del Virus Papiloma Humano en el marco del tamizaje virológico …

Mem. Inst. Investig. Cienc. Salud. 2019; 17(1):6-15 15

of human cancer. Vaccine. 2006;24(suppl 3):S1-S10.

Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikäheimo I et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA. 2001;285(1):47-51.

Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers IM et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC multicentric case-control study. Lancet. 2002;359:1085-92.

Castellsague X, Muñoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003; 31:20-8.

Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjosé S, Bruni L, Tortolero-Luna G, Krugar Kjaer S, Munoz N. Epidemiology and natural history of human papillomavirus infections and type specific implications in cervical neoplasia. Vaccine. 2008;26S:K1–K16.

Hibbitts S, Jones J, Powell N, Dallimore N, McRea J, Beer H, Tristram A, Fielder H, Fiander AN. Human papillomavirus prevalence in women attending routine cervical cancer screening in South Wales, UK: A cross-sectional study. Br J Cancer. 2008;99:1929–33.

Muñoz N, Bosch FX, de Sanjosé S, Shah KV. The role of HPV in the etiology of cervical cancer. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 1994;305(2):293-301.

Sharma K, Kathait A, Jain A, Kujur K, Raghuwanshi S, Bharti AC, et al. Higher prevalence of human papillomavirus infection in adolescent and young adult girls belonging to different Indian tribes with varied socio-sexual lifestyle. PlosS One. 2015 May 8;10(5):e0125693.

Vamos CA, Calvo AE, Daley EM, Giuliano AR y López Castillo H. Knowledge, Behavioral, and Sociocultural Factors Related to Human Papillomavirus Infection and Cervical Cancer Screening Among Inner-City Women in Panama. J Community Health. 2015 Dec;40(6):1047-56.

Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, Goodhill A et al. International Collaboration of Epidemilogical Sudies of Cervical Cancer: Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16.573 women with cervical cancer and 35.509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370(9599):1609-21

Almonte M, Albero G, Molano M, Carcamo C, García PJ and Pérez G. Risk factors for human papillomavirus exposure and co-factors for cervical cancer in Latin America and the Caribbean. Vaccine. 2008;26:L16-L36.

Castle PE, Jeronimo J, Schiffman M, Herrero R, Rodríguez AC, Bratti MC et al. Age-related changes of the cervix influence human papillomavirus type distribution. Cancer Research. 2006;66(2):1218-24.

Roeters AM, Boon ME, van Haaften M, Vernooij F, Bontekoe T and Heintz APM. Inflammatory events as detected in cervical smears and squamous intraepithelial lesions. Diagnostic cytopathology. 2010;38(2): 85-93.

Oliveira FA, Pfleger V, Lang K, Heukelbach J, Miralles I, Fraga F et al. Sexually transmitted infections, bacterial vaginosis, and candidiasis in women of reproductive age in rural Northeast Brazil: a population-based study. Memorias do Instituto Oswaldo Cruz. 2007;102(6):751-56.


Enlaces refback

  • No hay ningún enlace refback.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

Mem. Inst. Investig. Cienc. Salud